Addendum

Risankizumab (plaque psoriasis) - Addendum to Commission A19-41

Status
Status: Commission completed
Project no.
A19-87
Last updated

Report documents

  1. Addendum

    Risankizumab (plaque psoriasis) - Addendum to Commission A19-41

    published on
    Document type
    PDF document, 242 kB, EN, not accessible

Dossier assessment

Indication:

Adults with moderate to severe plaque psoriasis

Result of dossier assessment:

Conclusion of dossier assessment A19-41 unchanged

Additional information

Federal Joint Committee (G-BA)

2019-11-22 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A19-87
Commission
Commission awarded on 07.10.2019 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-41
    Last updated

    Status: Commission completed

  2. Addendum

    Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41

    Project no.
    G19-16
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form